ADAP - Why Shares of Adaptimmune Therapeutics Rose 13.4% on Tuesday
Shares of Adaptimmune Therapeutics (NASDAQ: ADAP) , a clinical-stage biopharmaceutical company that specializes in T-cell therapies to treat cancer, jumped 13.4% on Tuesday. The company's shares are down more than 58% so far this year.
The company reported positive proof-of-concept preclinical data on two of its new cell therapies after the market closed on Monday. Adaptimmune was presenting the data at an American Society of Gene & Cell Therapy conference. The news broke the day before the tech-heavy Nasdaq rose more than 2%. Those two factors drove the stock higher.
Image source: Getty Images.
For further details see:
Why Shares of Adaptimmune Therapeutics Rose 13.4% on Tuesday